Clinical trial
A Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon
NCT00498615 · Johns Hopkins University, Other · Completed
Key facts
| NCT number | NCT00498615 |
|---|---|
| Title | A Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon |
| Official title | Efficacy, Tolerability and Biology of a Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon |
| Lead sponsor | Johns Hopkins University, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Raynaud, Scleroderma |
| Intervention type | Drug |
| Interventions | Fasudil |
| Enrollment | 17 |
| Start date | Apr 1, 2007 |
| Primary completion | Mar 1, 2012 |
| Completion | Mar 1, 2012 |
| First posted | Jul 10, 2007 |
| Last update posted | Nov 4, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: